<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368262">
  <stage>Registered</stage>
  <submitdate>26/05/2015</submitdate>
  <approvaldate>18/06/2015</approvaldate>
  <actrnumber>ACTRN12615000634572</actrnumber>
  <trial_identification>
    <studytitle>An Assessment of Citramel in Healthy Volunteers </studytitle>
    <scientifictitle>A Open-label Assessment of the Safety of Citramel in Healthy Volunteers</scientifictitle>
    <utrn>U1111-1154-7443</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Citramel - an aqueous solution of sodium citrate (16.18 mg/mL), citric acid (0.046 mg/mL) and ammonium chloride (4.12 mg/mL). Administered by aerosol twice daily (morning and night) for 28 days. Compliance will be assessed by checking the vials returned by study participants.</interventions>
    <comparator>No comparator group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety as assessed by Adverse events, Vital signs, spirometry and Laboratory Tests</outcome>
      <timepoint> Screening and/or Baseline, then weekly to Day 28</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Participant diary records daily tolerability assessments during the study medication administration phase</outcome>
      <timepoint>Daily from baseline to Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>No secondary outcomes</outcome>
      <timepoint>N/A</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers aged 18-60 years who provide written informed consent; BMI 18-32 kg/m2; FEV1 between 80-120% of normal range; sexually active females must use contraception.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Clinically significant co-existing disease; current  or previously clinically significant smoking history; any medications (except oral contraceptives); ECG or blood pressure abnormalities; positive results on drugs of abuse or alcohol screen; greater than 15% improvement in FEV1 15 minutes post dose of bronchodilator at screening. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>After obtaining consent and confirming eligibility, the participant will be enrolled in the study. It is an open label assessments of Citramel in 5 healthy volunteers.  </concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods>This is a Phase 1 safety assessment of Citramel in five healthy volunteers and is not based on a formal sample size calculation. There are no formal statistical hypotheses associated with this open label assessment and  only descriptive statistics will be undertaken.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>6/07/2015</anticipatedstartdate>
    <actualstartdate>11/08/2015</actualstartdate>
    <anticipatedenddate>30/09/2016</anticipatedenddate>
    <actualenddate>17/08/2015</actualenddate>
    <samplesize>5</samplesize>
    <actualsamplesize>5</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>6/10/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Breathe Easy Ltd</primarysponsorname>
    <primarysponsoraddress>Ground Floor, Shed 20, 
139 Quay Street, 
Princes Wharf  
Auckland 1010
</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Breathe Easy Ltd</fundingname>
      <fundingaddress>Ground Floor, Shed 20, 
139 Quay Street, 
Princes Wharf  
Auckland 1010
</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NZVIF (New Zealand Venture Investment Fund)</fundingname>
      <fundingaddress>Unit 1B, Ascot Office Park, 93-95 Ascot Ave
Greenlane, Auckland 1051, New Zealand </fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a research study to evaluate Citramel inhalation. The study is an open label administration of Citramel to 5 healthy volunteers to evaluate safety and tolerability. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Health and Disability Ethics Committee.</ethicname>
      <ethicaddress>1 The Terrace
C/- MEDSAFE, Level 6, Deloitte House
10 Brandon Street
PO Box 5013
Wellington
6011</ethicaddress>
      <ethicapprovaldate>1/07/2014</ethicapprovaldate>
      <hrec>14/CEN/89</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Chris Wynne</name>
      <address>Christchurch Clinical Studies Trust (CCST)
31 Tuam Street
Christchurch 8011
</address>
      <phone>+64 3 372 9477 </phone>
      <fax>+64 3 372 9478</fax>
      <email>Chris@ccst.co.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Andrea Miller</name>
      <address>Breathe Easy Ltd, C/- Pacific Channel Ltd
Ground Floor, Shed 20, 
Equinox House, 
139 Quay Street, 
Princes Wharf  
Auckland 1010</address>
      <phone>+64 9 377 9689 </phone>
      <fax />
      <email>andreajmiller@gmail.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Andrea Miller</name>
      <address>Breathe Easy Ltd, C/- Pacific Channel Ltd
Ground Floor, Shed 20, 
Equinox House, 
139 Quay Street, 
Princes Wharf  
Auckland 1010</address>
      <phone>+64 9 377 9689</phone>
      <fax />
      <email>andreajmiller@gmail.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michelle Lockhart</name>
      <address>Ground Floor, Shed 20, 
Equinox House, 
139 Quay Street, 
Princes Wharf  
Auckland 1010</address>
      <phone>+64 21 665 947</phone>
      <fax />
      <email>michellelockhart@xtra.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>